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1. Introduction
Despite recent progress in the treatment of solid tumours by conventional therapeutic options
including surgery, chemotherapy, and radiotherapy, development of more efficient strategies
is urgently needed due to delimited efficacy and occurrence of severe side effects in current
treatment regimens. Cancer gene therapy can be defined as the introduction of genetic material
into the patient´s body for the purpose of reducing tumour burden, increasing life expectancy,
and improving the quality of life of the treated individual. It is most commonly intended to
either initiate tumour self-destruction, down-regulate angiogenesis and/or metastasis,
enhance anti-tumour activity of the immune system, suppress function of an activated
oncogene, or restore expression and/or function of tumour suppressor genes [1-4].
Viral vectors are the most widely used tools for the delivery of therapeutic genetic material
into host cells in a clinical setting. More than 65 % of gene therapy clinical trials worldwide
are making use of viral vectors (http://www.wiley.com). With almost 370 trials (~20 % of all
gene therapy clinical trials), gamma-retroviruses and in particular the murine leukaemia virus
(MLV)-based vectors are the second most used gene transfer system employed in recent years.
These vectors are able to transduce most cell types, as long as they are actively dividing.
However, most of these retroviral vectors are designed to be replication-deficient, resulting in
poor transduction efficiencies in vivo. This might be one, if not the reason for the poor
therapeutic success observed so far in clinical trials for cancer [5–7]. Thus, nowadays, replica‐
tion-deficient retroviral vectors are mainly used in ex vivo gene transfer for the treatment of
inherited monogenic disorders [8–10], rather than for in vivo tumour therapy.
However, to increase in vivo transduction efficiency and the poor therapeutic outcome
observed using replication-deficient retroviral (RDR) vectors, replication-competent retroviral
(RCR) vectors were created which allow vector production in the infected tumour cell and
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thus, as a consequence, efficient delivery of the therapeutic gene eventually to almost all target
cells (for review see [11-13]). Several research groups were involved in the design and
construction of such MLV-based RCR vectors and were able to show that these vectors are
well suited for efficient transduction of tumour cells and thus represent an efficacious
treatment option for tumour therapy.
In the following sections we will provide an overview on MLV-derived RCR vectors and their
therapeutic principle. Emphasis will be put on the different vector designs available and their
influence on vector spread kinetics, vector genome stability, and transgene expression levels.
Furthermore, strategies to target the vector by either selective infection of distinct cell types or
selective expression and replication of the vector genome and expression of the delivered
transgene in distinct cell types will be presented. Data from in vivo studies employing a set of
different therapeutic genes and targeting different tumour types in various animal models will
be reviewed and the therapeutic efficacy in these indications discussed. Finally issues regard‐
ing the safety of these vectors such as data from biodistribution and toxicological studies as
well as potential risks associated with such a therapy are addressed in the following.
2. Biology of the murine leukaemia virus
The murine leukaemia virus belongs to the genus of gamma-retroviruses which are small,
enveloped viruses carrying two copies of a single-stranded RNA genome within an icosaedric
core. The unique feature of retroviruses is their replication cycle, as their RNA genome is
reverse transcribed into DNA, which then integrates into the host DNA before being transcri‐
bed to give rise to new virus genomes and viral proteins. MLV is a so-called simple retrovirus
carrying only 3 genes in its genome, encoding the viral Gag, Pol and Env polyproteins. The
group-specific antigen Gag is processed by the viral protease (PR) to the matrix (MA), capsid
(CA) and nucleocapsid (NC) proteins which all form the viral core. The surface (SU) and
transmembrane (TM) proteins are processed from the Env protein and are embedded in the
host-cell derived lipid-bilayer. The pol gene encodes the viral PR, the reverse transcriptase
(RT) and the integrase (IN), which are delivered in the virus particle to the cell to be transduced.
After release of the virus core in the cytoplasm of an infected cell, reverse transcription of the
single-stranded RNA into double-stranded DNA takes place and the pre-integration complex
(PIC) consisting of virus DNA and viral and cellular proteins assembles [14]. As the MLV PIC,
in contrast to lentiviruses such as HIV, is not able to cross the nuclear membrane, productive
infection only occurs when the nuclear membrane is disrupted, as in dividing cells. Integration
of the viral DNA into the host genome occurs randomly, however an integration preference
of MLV-based vectors into the 5´-proximity of transcriptionally active genes was observed [15].
During reverse transcription identical long terminal repeats (LTRs) consisting of the so-called
U3, R, and U5 region and flanking the viral genes are created which carry the viral promoter
in the U3 region and the poly(A) site downstream of the R region. Expression from this
promoter leads to two RNA species, a genomic one also encoding the viral proteins Gag and
Pol, and the subgenomic env coding message. The Gag and Pol proteins assemble together
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with the genomic RNA which is recognized by Gag via a packaging signal present immediately
downstream of the 5´-LTR. Newly synthesized virus particles exit the cell via budding through
Env protein-rich regions of the host cell membrane without lysis of the cell.
Thus, due to its non-lytic nature retroviruses per se cannot be used as so-called oncolytic
viruses, which are able to kill tumour cells by their productive infection only, but require
additional gene sequences to exert a tumour destroying effect. Such therapeutic replication-
competent MLV vectors can only be generated by adding therapeutic sequences in addition
to the viral genes, which are all essential for virus replication, making the design of such vectors
challenging and their genomic stability critical due to genomic overlength.
3. Replicating MLV vectors
3.1. Vector designs, spread kinetics and genome stability
Early attempts to produce replication-competent retroviral vectors have been already made
in the late 80´s of the last century, when various groups inserted a transgene expression cassette
into the 3´-LTR of replicating MLV to generate a research tool for analyses in whole-animal
models [16-18]. During infection and reverse transcription of the proviral mRNA message, the
transgene expression cassette was duplicated and, now present in the 5´- and 3´-LTR, inde‐
pendently expressed from the respective heterologous promoter. An RCR containing a mutant
form of the dihydrofolate reductase (DHFR) gene was shown to stably transmit methotrexate
resistance to infected fibroblasts upon multiple rounds of virus replication in vitro in the
absence of drug selection and was produced at high titres by fibroblast cells [16].
Later, the group of Finn Skou Pedersen adopted this concept and inserted the transgene within
the U3 region of the 3´-LTR of the Akv strain of MLV, mediating expression of the eGFP-
transgene via an internal ribosomal entry site (IRES) of the encephalomyocarditis virus
(EMCV) (Figure 1, (B)) [19]. This design again resulted in doubling of the IRES-transgene
cassette in the infected cell, albeit, only the eGFP gene located in the 3´-LTR, but not the
transgene present in the 5´-LTR, was expressed from the regulatory elements in the MLV 5´-
LTR. Intraperitoneal injection of this vector at a concentration of 10e4 colony forming units
into 3-4 days old mice led to more than 50 % eGFP-expressing spleen cells 4 days after injection.
The level of eGFP-positive cells remained constant till day 7, but dramatically dropped from
day 12 onwards, most likely to genetic instability of the vector and reversion to wild-type (wt)
virus lacking the marker gene [20].
Due to the highly compact nature of the MLV genome, however, the positions into which
heterologous sequences can be inserted without impacting on viral replication are limited.
Thus, up to now only few vector designs in which the transgene is located at different positions
and/or its expression is facilitated by different mechanism have been created and are currently
under in-depth evaluation.
Kasahara and colleagues favoured insertion of the transgene right downstream of the en‐
velope reading frame, as well  linked via an ECMV IRES element (Figure 1,  (C))  [21,22].
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These RCR vectors are based on the Moloney strain of MLV and are equipped with the
amphotropic  MLV envelope  gene,  both  of  which  are  features  allowing  infection  of  hu‐
man and other  mammalian  cells.  The  effect  of  insert  size  and  sequence  on  the  genetic
stability and spread efficacy of the vector revealed a strong negative correlation between
insert  size and deletion of  the introduced sequence.  Insertion of  1.6  kb in length led to
greatly  attenuated  replication  kinetics  relative  to  wild-type  virus  and  loss  of  the  insert
within  a  single  infection  cycle,  whereas  inserts  up  to  1.3  kb  were  well  tolerated  with
slightly attenuated replication kinetics. In addition, the genomic integrity was maintained
over multiple serial infection cycles [21,22].
Figure 1. Schematic depiction of the different RCR vector designs ((B) – (F)). The inserted transgene is located at
different positions in the viral vector and expression is facilitated by different means. (A) represents the genomic or‐
ganisation of the wt-MLV provirus. LTR = long terminal repeat; gag = viral group specific antigen gene; pol = viral poly‐
merase gene; env = viral envelope gene; IRES = internal ribosomal entry site; TG = transgene; F = protein cleavage site;
SD = splice donor; SA = splice enhancer; ψ = psi packaging site; Pol III Prom = Polymerase III dependent promoter.
To further unravel the effects of viral strain and transgene position in the vector, as well as the
impact the target cell type might have on spread kinetics and on the genetic stability of the
virus vector in particular, we have independently compared the different parameters in serial
rounds of infection in different cultured cell types as well as in vivo in tumour bearing animals
[23]. To this end, various cell lines have been inoculated with RCR vectors based on the Akv
and Moloney strain of MLV and carrying an IRES-EGFP transgene cassette either in the U3
region of the 3´-LTR or immediately downstream of the env gene, and passaged and monitored
over time. Supernatant of the infected cells was also used to infected fresh cells for a further
round of infection to allow exponential spread of virus vector until a maximum of EGFP-
expressing cells was reached. Supernatant of the freshly infected cells was then used for a next
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round of infection to finally end up with more than 20 rounds of infection, and virus propa‐
gation for up to 100 days. The obtained data revealed a clear advantage of the Moloney-MLV
strain over the Akv-MLV strain in respect to spread kinetics, transgene expression and vector
stability and demonstrated that location of the transgene immediately downstream of the env
gene is preferred in respect to genomic stability of the vector. These observations have been
confirmed in spread and stability analyses after virus injection in tumour xenografts of mice
[23]. Unexpectedly, our results also indicated that the host cell can influence the ability of MLV-
based RCR vectors to stably propagate the expression of heterologous genes, since all vectors,
regardless of design, lost the ability to express eGFP in NIH-3T3 cells much more rapidly than
in HEK-293 cells [23]. Differences in vector genome stability between infected cell lines seem
to be dependent neither on species nor on different replication kinetics of the vector in the
respective cell lines. It rather might be due to differences in other virus and/or host-cell features
including fidelity of the virus reverse transcriptase linked with the p53 status of the infected
cells, expression of the anti-viral mechanisms such as APOBEC and TRIM family members,
availability and balance of intracellular dNTP pools, and in general, due to an overall genetic
instability of certain cell types and cell lines [24].
Employing this design in which the heterologous sequences are located in the 3´-untranslated
region immediately downstream of the env reading frame, expression of the transgene could
also be facilitated by introducing, instead of the IRES, a splice acceptor site upstream of the
transgene, which would result in a transgene specific mRNA message (Figure 1 (D)) [25].
Propagation of such vectors in cell culture however, revealed a much slower vector spread as
compared to the IRES-carrying vector, which led to almost 100% infected cells after 3 days
after infection [25].
RCR vectors based on Mo-MLV carrying a therapeutic gene in the 3´-untranslated region
resemble currently the most advanced RCR vector design for tumour therapy and are already
employed in the first clinical trial for the treatment of cancer.
A different approach in the design of RCR vectors has been pursued by the group of Christian
Buchholz from the Paul-Ehrlich-Institut, as they inserted heterologous sequences including a
3´-terminally located furin cleavage site in frame into the envelope gene of the virus between
the signal peptide and surface protein domain coding region (Figure 1, (E)) [26,27]. During
production of the Env protein in virus vector transduced cells, the heterologous amino acid
sequence will be cleaved off while the Env protein is processed through the secretory pathway
and eventually will be secreted from the infected cell. Proof-of-concept for this vector design
was shown with the immune stimulatory cytokine GM-CSF and the laminin-specific or T-cell
specific single-chain antibody variable region fragment (scFv) [27]. The resulting viruses
infected a variety of human cell lines and infectious virus particles were detected in superna‐
tants of infected cells. Moreover, these cells were able to efficiently process the encoded Env-
fusion proteins and to release reasonable amounts of protein molecules of GM-CSF, laminin-
specific or T-cell specific scFvs into the cell culture media. Furthermore, the replicating viruses
were genetically stable for at least 12 serial cycles of propagation. Thus, these vectors are ideally
suited for production of therapeutic factors which need to be secreted, but less suitable in case
the protein produced is intended to be active in the infected cell.
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An additional site for integration of foreign sequences into the vector genome without
impairing virus life cycle is the proline-rich region tract within the Env protein (Figure 1, (F)).
Insertion of the eGFP marker gene into this site in a Mo-MLV-based RCR vector resulted in
spread through almost 100% of cultured NIH-3T3 cells within one week after initial transfec‐
tion with virus sequences [28,29]. PCR analysis of integrated virus vector DNA from chroni‐
cally infected cells indicated no genetic recombination in the modified env gene region. An
additional insertion of a Pol III promoter-shRNA expression cassette in antisense orientation
into the 3´-untranslated region of the virus vector resulted in only slightly reduced spread
kinetics as compared to the parental vector and in delivery and functional expression of the
shRNA in most of the cells [30]. Again PCR analysis did not reveal any recombination events
over 4 infection cycles.
3.2. Targeting of infection and expression
MLV-based RCR vectors can be accounted for being intrinsically tumour-selective due to the
specific nature of MLV to replicate in dividing cells only. Nevertheless, it would be desirable
to further improve the vector safety profile. This can be achieved by introducing transcriptional
control elements that restrict RCR gene expression and subsequent virus vector replication to
tumour cells - so-called transcriptional targeting; or by modulating the interaction of the RCR
vector with host cells at the very early step of the infection process, known as physical targeting,
via adaptation of the virus envelope glycoprotein to selectively bind to surface molecules
exclusively or predominantly present on cancer cells. Alternatively, initial targeting could also
be enabled by the use of delivery vehicles to facilitate transport or homing of the RCR vectors
to the tumour site.
3.2.1. Transcriptional targeting
To allow transcriptional targeting of MLV-based RCR vectors, the most reasonable approach
is the exchange of the ubiquitously active viral promoter located in the U3 region of the viral
LTR by a tissue- or tumour-specific promoter delimiting its activity and thus virus vector
replication to a specific cell type. Due to the particularities of retroviral reverse transcription,
modifications of this promoter must be introduced into the U3 region of the 3’-LTR. This
allows, after initial vector production and infection, duplication of the regulatory elements
into the 5´-LTR (Figure 2). This strategy has been successfully employed previously in
conventional replication-defective retroviral vectors to direct transgene expression to a
particular cell type [31–33]. In RCR vectors however, not only expression of the transgene
sequences is mediated by these regulatory elements, but also expression of viral genes which
are needed to ensure efficient RCR vector replication in infected target cells and which have
to be produced in an ample but well balanced manner. Moreover, as the LTR contains
regulatory elements important for reverse transcription, RNA processing, and virus genome
integration, modifications in this area may interfere with or may disrupt these elements and
may thus negatively affect virus replication kinetics. This altogether renders the transcriptional
targeting approach for RCR vectors rather complex.
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Figure 2. Principle of transcriptional targeting of RCR vectors. (A) schematically depicts the RCR proviral genome
as present in a virus producer cell. The tumour- or tissue-specific regulatory sequence (specific promoter) is located in
the 3´-LTR of the viral vector. After infection and reverse transcription of the virus genome, the 3´-LTR U3 region is
duplicated to the 5´-LTR and is thus able to drive expression of the viral genes and of the inserted transgene (B). For
abbreviations please see legend to Figure 1.
In early studies, the murine liver-specific transthyretin promoter/enhancer was inserted into
the LTR U3 region, lacking the endogenous enhancer, of a replication-competent MLV [34].
When compared to wt-MLV however, the recombinant virus did not reveal an improved rate
of infectivity of hepatocytes in vitro or a restricted tissue tropism in vivo [34].
Transcriptional targeting of MLV-based RCR vectors harbouring modifications in the U3
region by insertion of  a  heterologous promoter  was demonstrated initially  by Kasahara
and colleagues [35]. In these vectors, hybrid LTRs were constructed by replacement of the
MLV 3´-LTR U3 region from the very 5’ end to either the CAAT box, the TATA box, or
the transcriptional start site (TSS) by a heterologous promoter complementing the deleted
boxes, respectively. Using a highly prostate-specific rat probasin (PB) proximal promoter
and a synthetic variant of this promoter containing several copies of the androgen respon‐
sive  region  (ARR2PB),  respectively,  virus  gene  expression  and  virus  production  was
shown to be restricted to prostate cancer cells in vitro [35]. Replication of vectors in which
the heterologous promoter was fused directly to the MLV TSS was greatly impaired rela‐
tive to that of vectors in which the viral CAAT and TATA box, or the viral TATA box on‐
ly, was retained. The configuration in which the MLV TATA box was preserved, but all
upstream elements had been replaced by heterologous regulatory sequences was found to
be ideal in respect to transgene expression, vector spread and specificity [35]. The use of
the stronger ARR2PB promoter resulted in a greatly improved efficacy of vector replica‐
tion [35]. Moreover, results from biodistribution studies in immunocompetent and immu‐
nodeficient mice indicated that this targeting strategy prevents the productive spread of
RCR vectors to spleen and bone marrow of systemically infected mice [12].
Using a different set of promoter/enhancer elements, Metzl et al. were able to demonstrate that
MLV-based RCR vectors can also be targeted to liver cancer cells and to tumour cells har‐
bouring a deregulated ß-catenin signalling pathway [36]. Vectors equipped with a chimeric
promoter consisting of the hepatitis B virus enhancer II fused to the human α1-antitrypsin
promoter (EIIPa1AT promoter) revealed a substantial spread in the liver cancer cell lines
HepG2, AKH12, AKH13, but replicated only scarcely in the colon carcinoma cell lines SW480
and DLD-1, the cervical cancer cell line HeLa and the human embryonic kidney cell line
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HEK-293 [36]. Similarly, vectors equipped with the synthetic beta-catenin/T-cell factor
dependent CTP4 promoter replicated in the ß-catenin deregulated cancer cell lines HepG2,
SW480, and DLD-1, but not in the cell lines AKH12, AKH13, HeLa, and HEK-293, which
revealed a normal ß-catenin signalling pathway. When the heterologous promoters were used
to replace almost the entire U3 region, including the MLV TATA box and TSS (TATA-
replacement (TR) design), vector replication was inefficient as virus particle production from
infected cells was clearly reduced by factor 100 as compared to a vector harbouring the wt-
MLV 3´-LTR. On the contrary, fusion of the heterologous promoter lacking the TATA box to
the MLV TATA box (TATA-fusion (TF) design) generated vectors which replicated with almost
wt-MLV kinetics throughout permissive cells despite the fact that virion production from
infected cells was reduced by 10-fold as compared to the prototype vector ACE-GFP. As
expected, these TF-vectors exhibited low or negligible spread in non-permissive cells. The
genomic stability of the TF-vectors, however, was shown to be comparable to those containing
wt-MLV LTRs [36].
Both studies indicated that the precise manner in which the heterologous promoters are
inserted into the U3 region of the 3´-LTR is of paramount importance. Only vectors retaining
the MLV TATA box in its natural position exhibited both regulated gene expression and rapid
replication kinetics [35,36].
3.2.2. Physical targeting
For decades it was generally accepted, that with MLV, and as a consequence, with MLV-based
vectors, infection can only take place in dividing cells. Therefore, such vectors can be a priori
accounted as intrinsically tumour-selective in the appropriate environment. However, very
recently Liu et al. reported infection of neurons and growth arrested neuroendocrine cells with
MLV-based RCR and RDR vectors harbouring an amphotropic envelope at efficiency similar
to that of lentiviral vectors, which are known to infect also non-dividing cells [37]. This new
and unexpected observation, if confirmed, will further raise the need for retrovirus vectors
with a specific and/or targeted infection and/or replication range.
Retroviruses are unique among viral vectors in their capacity to incorporate a wide range of
envelope proteins from other retroviruses and even from completely unrelated virus types.
Insertion of heterologous envelope proteins into the outer shell of viral particles, so called
pseudotyping, to exert an infection targeting approach has already been demonstrated in RDR
vectors for a variety of envelope molecules [38–40]. The MLV-based RCR vectors used in cancer
gene therapy applications to date are mostly based on the Moloney strain of MLV, which
naturally expresses the ecotropic MLV envelope and thus are able to only infect rodent cells.
To allow infection of human cells, the vectors are pseudotyped with the amphotropic envelope
gene from the 4070A strain of MLV, which can infect most mammalian cell types via the
ubiquitously-expressed Pit-2 receptor [41]. Logg and colleagues also replaced the native env
sequence with that of the gibbon ape leukaemia virus (GALV) retaining a short portion of the
signal peptide coding sequence of the MLV Env to avoid alteration of the MLV polymerase
reading frame which is overlapping with the 5´-end of the envelope reading frame [42]. This
env gene replacement greatly attenuated viral replication, most probably by a large clearance
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in splicing of the viral RNA. However, employing an in vitro evolution strategy, extended
passaging of cells exposed to the chimeric virus resulted in selection of virus mutants with
rapid replication kinetics. Different variants arose from different sets of infection experiments.
None of the revertants exhibited mutations in the GALV env gene itself, but rather in other
areas of the virus to retain the ratio of spliced to unspliced viral messages which had been
pertubated by the substitution of the env gene [42].
An alternative strategy for changing the tropism of MLV-based RCR vectors is via direct
engineering of the specific targeting ligand sequence within the env gene. Again, several
strategies have been demonstrated for RDR vectors, including the incorporation of ligands or
single chain antibodies into the env gene to allow targeting to an alternative receptor [43-45].
However, these approaches were of limited success in respect to transciptional targeting, as,
although retargeting of the vector was achieved, infection efficiency was greatly reduced, since
the conformational change in the envelope protein necessary for proper virus-cell fusion failed
to happen subsequently to the binding of the modified envelope to the alternate receptor [46].
In another approach to allow the physical targeting of RCR vectors, two tandem repeats of the
immunoglobulin G-binding Z-domains of Staphylococcus protein A were inserted into the
proline-rich region of amphotropic or ecotropic MLV envelope proteins present in MLV-based
RCR vector particles, respectively [47]. This approach should allow virus particles to be
conjugated to an antibody of choice, which can then be used for the selective binding of virus
to cells (over)-expressing the chosen antibody target. Modified envelopes were efficiently
expressed and incorporated into virions, while infectivity was markedly reduced by this
pseudotyping [47].
For RCR vectors the most efficient physical targeting system up to now is based on protease-
activatable envelope proteins [48]. Rather than attempting to redirect infection to target cells
by incorporation of specific binding domains into the envelope protein, here, the virus remains
non-infectious until the Env proteins become activated by cleavage by a secreted or membrane-
bound cellular protease recognizing the protease target site present in the engineered Env
molecule. A directed evolution-based approach was employed for the selection of retroviruses
activatable by matrix metalloproteinases (MMPs) which are specifically expressed by tumour
cells [26,49,50]. RCR vectors generated to express either the epidermal growth factor (EGF) or
the CD40 ligand, linked via MMP cleavage sites as fusion to the N-terminal of the MLV 4070A
envelope protein, were sequestered by the EGF receptor or the CD40 receptor, which are
ubiquitously-expressed on potential host cells. By that the envelope protein was prevented
from interacting with its natural Pit-2 receptor resulting in poor infection efficiencies and thus
de-targeting of the RCR vectors from non-tumour cells [49,50]. Infection efficiency however,
is restored in cells which express high levels of MMPs, such as many tumour cell types, due
to Env-ligand cleavage and interaction of the Env protein with its natural receptor [50]. In a
comparative study Duerner and colleagues analysed the spread of targeted and non-targeted
MLV RCR variants in s.c. tumours derived from HT1080 and U-87MG cells, respectively, and
in extratumoral organs after systemic tail vein injection of the vector into SCID mice [48]. Both
virus types were able to efficiently infect tumour cells however, the non-targeted virus
efficiently infected also extratumoral organs such as bone marrow, spleen, and liver. Quanti‐
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tative analyses revealed an up to 500-fold higher selective infection of tumour tissue with the
targeted viruses than with the non-targeted counterpart [50].
3.2.3. Alternative ways for RCR vector targeting
Recently, a fully functional chimeric vector system that uses a helper-dependent adenovirus
5 (Ad) vector as a first stage carrier to express and deliver a fully functional RCR vector has
been described [51]. The RCR vectors are produced in situ from initially adenovirus-transduced
cells, thereby combining benefits of both vector systems – high titers reached with adenovi‐
ruses and stable integration of retroviruses. At equivalent initial transduction levels, more
secondary RCR progeny were produced from Ad-RCR-transduced cells as compared to RCR-
transduced cells, resulting in further acceleration of RCR replication kinetics [51]. In pre-
established s.c. human breast cancer xenografts in mice, suicide gene therapy with high titre
chimeric Ad-RCR vectors achieved, in a dose dependent manner, an enhanced efficacy
compared to delivery of respective RCR-only vectors [52]. As the target cell binding tropism
of adenoviral vectors can be altered by modifications to the fibre knob [53], the strategy of
employing a chimeric Ad-RCR vector system might represent a promising step forward
towards a targeted and efficacious cancer gene therapy.
As a future option, delivery of RCR vectors to tumours could also be facilitated by the use of
tumour-homing cells as vector carriers. Mesenchymal stromal cells, for example, which have
been shown to be able to home to malignant areas, have been loaded with replicating adeno‐
viral vectors to deliver them to the tumour tissue to execute their oncolytic potential [54], an
approach which might be also applicable to RCR vectors.
3.3. Therapeutic application of MLV-based RCR vectors
Despite the fact that the first experiments employing MLV-based RCR vectors have been
commenced more than 20 years ago, the utilization of these vectors for cancer gene therapy is
still at an early stage. The vectors are not oncolytic per se and the choice of therapeutic genes
which can be used is limited, as large heterologous sequences cannot be inserted into the MLV
genome without impairing vector stability and replication efficiency. Nonetheless a number
of therapeutic sequences such as those encoding suicide genes, cytokines and interfering RNAs
have been demonstrated to be stably propagated over several infection cycles by MLV-based
RCR vectors.
3.3.1. Suicide genes
Suicide genes, also called prodrug-converting genes, encode proteins which are not toxic per
se, but which are able to catalyse the formation of toxic metabolite(s) from a non-toxic or low-
toxic prodrug. By the delivery of suicide genes to and their expression in tumour cells,
conversion of a systemically administered prodrug by the respective suicide gene product
results in a highly specific and effective anti-tumor therapy [55]. Although the toxic metabolites
generated are quite often identical to those of classical chemotherapy, here, the local produc‐
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tion of metabolites in the tumour cells results in a more contained and specific effect as
compared to the, in most cases, systemically given chemotherapy.
Initial data demonstrating therapeutic efficacy of an RCR vector mediated suicide therapy
approach have been shown using the yeast cytosine deaminase (yCD) gene in a mouse model
of human glioma [56]. In cells infected with the yCD expressing RCR vector ACE-CD, the non-
toxic prodrug 5-fluorocytosine (5-FC) was converted into the toxic component 5-fluorouracil
(5-FU), leading to cell death not only in infected cells but also in surrounding non-infected
dividing cells due to intercellular diffusion of 5-FU. Stereotactic intratumoral injection of only
1x10e4 infectious ACE-CD particles into pre-established intracranial U-87MG human glioma
xenografts in nude mice followed by daily intraperitoneal (i.p.) administration of 500 mg 5-FC
per kg body weight eight days later for 15 days (ACE-CD + 5-FC) led to survival of all treated
animals for a follow up period of 60 days, whereas mice of both control groups, vector only
(ACE-CD + PBS) and prodrug only (PBS + 5-FC), died within 40 days [56]. Subsequent studies,
however, revealed that this treatment regimen is insufficient to get complete eradication of
U-87MG tumours in the treated animals, resulting in death of the animals after 70 and more
days [57]. Retrospective immunohistochemical analyses showed that in most of the treated
animals still small areas of tumour tissue were present indicating an ectopic spread of glioma
cells in the brain. Despite the fact that all of the surviving tumour cells stained positive for viral
envelope protein, these tumour cells had not been killed by the administration of 5-FC. This
suggests that these cells either have been infected with a suicide gene deletion variant of the
vector or the therapeutic gene, although present, is not expressed in these cells or that the cells
are refractory to chemotherapy [57]. Tai et al. also examined whether the efficacy of this
treatment could be increased by administering multiple cycles of 5-FC [57]. To this end, after
injection of 1x10e4 transducing units of vector ACE-CD into preformed intracranial tumours,
mice received multiple cycles of 5-FC for 8 consecutive days with 3-week intervals between
the treatment periods [57]. Again, all control animals receiving virus vector only and prodrug
only, respectively, died within 40 days, whereas all mice treated with vector and prodrug
survived for more than 100 days, demonstrating that the multi-cycle strategy provides a
significant therapeutic benefit compared to a single cycle of prodrug administration [57].
To investigate the effect of the immune system on the effectiveness of the RCR vector-mediated
glioma therapy, the rat glioma cell line RG2 was used to establish syngeneic intracranial
tumours in Fischer 344 rats [58]. Three days after tumour implantation, 1x10e6 infectious ACE-
CD virus particles were stereotactically injected into the growing tumours. Ten days after virus
injection, 5-FC at 500 mg/kg body weight was administered i.p. for 7 consecutive days and after
a 10 days interval the treatment cycle was repeated. Animals treated with vector ACE-CD and
5-FC survived for up to 35 days, whereas control animals (ACE-CD + PBS) died within 21 days.
Despite the higher initial virus vector load injected into the tumour and the shorter intervals
between the treatment cycles a significantly shorter survival time of treated Fischer 344 rats
was observed as compared to data of vector/prodrug treated U-87MG tumour bearing nude
mice [58]. This observation might be, to a certain extent, due to reduced spread kinetics in the
RG2 tumour as compared to the U-87MG tumours, as only 65 % of RG2 tumour cells got
transduced after 21 days after initial virus infection. On the other hand, animals with tumours
Replicating Retroviral Vectors for Gene Therapy of Solid Tumors
http://dx.doi.org/10.5772/54861
139
derived from pre-infected and 100 % CD-expressing cells treated with 5-FC died due to tumour
burden at a significantly later time point, however still within 50 days [58]. This indicates that
other factors might contribute to the poorer treatment efficacy, such as insufficient levels of 5-
FC/5-FU in the tumour, differences in resistance to 5-FU, or effects triggered by the immune
system. Regarding this latter point, however, no immune response against the RCR vector in
the brain has been detected [58].
Recently,  we have critically  analysed a  panel  of  15  different  human and rodent  glioma
and glioblastoma cell lines in respect to spread of RCR vectors derived from vector ACE-
CD  to  their  sensitivity  towards  the  5-FC/5-FU  suicide  system,  and  to  their  orthotopic
growth characteristics  in  mice  to  identify  suitable  preclinical  animal  models  as  test  bed
for  the  development  and evaluation  of  RCR vector  mediated treatment  of  glioblastoma
[59]. Rapid virus spread was observed in eight out of nine human cell lines tested in vi‐
tro.  As  expected,  only  CD-expressing  cells  became  sensitive  to  5-FC.  All  LD50  values
were within the range of concentrations obtained in human body fluids after convention‐
al 5-FC administration. In addition, a significant bystander effect was observed in all hu‐
man glioma cell lines tested, supporting the potential of this suicide gene therapy for the
treatment of brain tumours [59].
This therapeutic concept has also been experimentally employed to subcutaneous and or‐
thotopic  liver  metastasis  of  colorectal  cancer  in  an  immunocompetent  rodent  model
[60,61].  To this end, murine CT26 cells pre-transduced with vector ACE-CD were mixed
with  non-transduced  CT26  cells  at  a  ratio  of  1:200  prior  to  implantation  into  BALB/c
mice.  Twelve days later,  daily 5-FC treatment at  500 mg/kg, given i.p.  twice a day,  was
started and continued until the end of the experiment. 5-FC treated animals showed sig‐
nificant inhibition of tumour growth resulting in an average tumour size of approx. 100
mm3  at  day  24,  whereas  in  animals  whose  drinking  water  was  supplemented  with  0.4
mg/ml of azidothymidine (AZT) to prevent MLV vector replication, tumour growth was
inhibited  only  moderately  with  an  average  tumour  size  of  approx.  500  mm3  at  day  24
[61].  Tumour size in untreated animals reached more than 800 mm3  at  day 24 [61].  The
effect on tumour size observed in the AZT-treated group most probably was due to the
presence  of  a  bystander  effect,  in  which toxic  metabolites  produced by the  CD-positive
cells  can  freely  diffuse  into  neighbouring,  CD-negative  cells  to  cause  cell  death  and
thereby eventually lead to a delay in tumour growth. These observations clearly indicate
that  the  efficacy  of  the  ACE-CD/5-FC  treatment  is  dependent  on  a  sustained  vector
spread. Proof-of-concept of this therapy was also shown in a multifocal hepatic metasta‐
sis model [61]. Here, CT26 cells stably expressing the firefly luciferase marker gene were
infused into the portal system via intrasplenic injection, became trapped within the hep‐
atic microcirculation, and seeded metastases. Three days later, 2x10e4 ACE-CD virus vec‐
tor  particles  were  instilled  into  tumour-bearing  mice,  again  via  intrasplenic  injection,
followed by daily  5-FC administration at  500  mg/kg given i.p.  twice  a  day,  initiated 14
days  after  tumour  cells  inoculation  [61].  In  contrast  to  untreated  animals  or  animals
which  received  vector  and  PBS  only,  and  which  revealed  increasing  bioluminescence
throughout the 28 day experiment, 5 out of 7 animals treated with both vector ACE-CD
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and 5-FC showed stable  or  decreased levels  of  bioluminescence,  indicating that  the  de‐
velopment of metastases was inhibited [61].  The locoregional delivery of the CD suicide
gene  by  RCR  vectors  infused  into  the  portal  circulation  thus  resulted  in  progressive
transduction of multiple tumour foci in the liver without evidence of spread to adjacent
normal parenchyma or extrahepatic tissues as shown by qPCR analyses of MLV-specific
sequences in the DNA of liver tumour tissue, normal liver, and bone marrow cells [61].
For proof-of-concept in a further indication, Kikuchi and colleagues evaluated the transduction
and therapeutic efficacy of intravesically administered RCR vectors in orthotopic bladder
tumours in mice [62]. Tumours were established by implantation of either MBT-2 murine
bladder cancer cells into immunocompetent syngeneic C3H/HeJ mice or of KU-19-19 human
bladder cancer cells into nude mice. RCR vector particles carrying the eGFP transgene were
delivered intravesically via a catheter inserted into the bladder 5 days after tumour formation.
Upon injection of 3.2x10e5 infectious virus particles, vector spread in the human xenograft
model reached almost all of the tumour cells within 35 days post infection [62]. In the orthotopic
syngeneic model, vector spread resulted in, on average, 30 % of infected tumour cells 27 days
after vector instillation, as revealed by immunohistochemical analyses of transgene expression
[62]. The effects of the respective therapeutic vector ACE-CD were demonstrated in the MBT-2
bladder cancer model, whereby 3.2x10e5 infectious virus particles were instilled intravesically
into the bladder of mice containing preformed tumours. Twelve days following infection,
animals received daily 5-FC at 500 mg/kg given i.p. for 15 days [62]. A single course of 5-FC
treatment led to significantly reduced tumour growth and 50 % of the animals survived for
more than 70 days. In contrast, all of the animals in vector only or vehicle control groups died
within 40 days. Again, the locoregional delivery of intravesically administered RCR vectors
was shown to achieve significant tumour growth inhibition by efficient delivery of the
therapeutic gene into the orthotopic bladder tumour cells without any evidence of spread to
adjacent distant organs [62].
Recently, Kawasaki et al. investigated RCR vector mediated gene therapy for the treatment of
human malignant mesothelioma [63]. Cells of this tumour type were found to be highly
permissive for RCR infection [63]. After a single intratumoral injection of 1x10e4 ACE-CD virus
vector particles into pre-established subcutaneous MSTO-211H human mesothelioma tumour
xenografts in nude mice, followed by daily 5-FC administration at 500 mg/kg body weight
given i.p. from day 12 to day 32 post-infection, significant inhibition of tumour growth was
observed in ACE-CD/5-FC treated mice compared to control groups as indicated by a tumour
volume of 200 mm3 vs. 800 mm3, respectively, at day 32 after infection. Efficacy of the treatment
was also investigated in a peritoneally disseminated human mesothelioma xenograft model
[63]. Here, MSTO-211H cells stably expressing the mCherry fluorescence protein and trans‐
duced with vector ACE-CD were mixed at a ratio of 1:100 with non-transduced mCherry
expressing MSTO-211H cells and the mixture was injected i.p. into nude mice. After confir‐
mation of tumour formation by in vivo imaging, daily 5-FC administration was initiated (500
mg/kg i.p.) for 15 consecutive days. In 4 out of 9 mice of the vector/5-FC receiving group no
visible tumours were observed and mice survived until day 100 after cell injection. On the
contrary, all non-treated mice had died at day 61 at the latest. In summary, the 5-FC treated
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group showed a significantly prolonged median survival time as compared to the control
group (81 days vs. 34 days) [63].
Beside the CD/5-FC suicide gene/prodrug combination, which is the most prominent and ex‐
tensively studied system in context of RCR vectors, other therapeutic genes have been intro‐
duced  in  this  vector  system  and  have  been  analysed.  The  bacterial  purine  nucleoside
phosphorylase (PNP) gene, for example, converts the prodrugs fludarabine phosphate (F-ara‐
AMP) or 6-methylpurine 2´-deoxyriboside (MeP-dR) into its toxic metabolites and represents
a reasonable alternative to the CD/5-FC suicide system. Kikuchi et al. demonstrated the thera‐
peutic efficacy of vector ACE-PNP, an MLV-based RCR vector expressing the E.coli PNP
gene, in a subcutaneous model of KU-19-19 human bladder cancer cells in nude mice [64]. Five
days following tumour cell implantation, 3.2x10e5 infectious virus particles were injected di‐
rectly into the tumour and 10 days later F-araAMP at 75 mg/m2 body surface was adminis‐
tered i.p. every other day for a total of seven injections. Significant tumour growth inhibition
could be demonstrated with a tumour mass of 600 mm3 vs. ≥ 2,200 mm3 at day 26 post virus in‐
jection in treated mice vs. vector and vehicle control groups [64]. These results indicate that the
PNP-RCR system is a reasonable alternative to the use of CD-expressing RCR vectors, in par‐
ticular as enzymatic products generated by PNP seem to be more cytotoxic than 5-FU [65,66].
In in vitro experiments using human U-87MG glioma cells, Tai and colleagues were able to
show that transduction of even only 1 % of cells with the ACE-PNP vector and subsequent
systemic prodrug administration is sufficient to achieve significant cell killing over time [67].
Thereby, the rapidity of cell killing is highly dependent on the initial level of transduction.
Treatment of pre-established s.c. U-87MG tumour xenografts with 1x10e5 ACE-PNP vector
particles followed by F-araAMP prodrug administration 14 days after virus injection at a
concentration of 80 mg/kg given i.p. once every other day for five times resulted in significantly
inhibited tumour growth [67]. A second cycle of prodrug administration reduced tumour
growth even further. The potential of an ACE-PNP RCR vector-based therapy to improve
survival of nude mice bearing intracranial U-87MG tumours was evaluated by inoculating
pre-established xenografts with 1x10e4 vector particles 7 days after tumour onset. Eight days
later, the mice received F-araAMP (40 mg/kg given i.p. once every other day) for a total of eight
treatments. The median survival time was 59 days vs. 30 and 28 days in treated vs. control
groups [67]. In a second experiment, the same experimental setting was employed, but a second
round of F-araAMP treatment was done after a 14 days recovery period. The median survival
time of treated mice was further improved to 73 days vs. 33 days in the control groups [67].
This data again demonstrated the potential for additional survival benefit from multiple cycles
of prodrug administration.
In summary, the published data of non-preclinical studies using suicide gene-expressing MLV-
based RCR vectors have demonstrated that such vectors are therapeutically efficacious in solid
tumours and/or metastases of a range of different tumour types (glioma, colorectal and bladder
cancer, mesothelioma) in both immunodeficient and immunocompetent mouse and rat
models, and using different therapeutic genes (yCD and PNP). On grounds of these non-
clinical data the therapeutic concept of replicating retroviral vectors was moved towards
clinical application. To this end, based on the design of the extensively evaluated vector ACE-
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CD, a lead clinical candidate (vocimagene amiretrorepvec, Tocagen Inc., San Diego, CA) has
been constructed carrying a human codon-optimised thermostable yeast CD gene [68].
Comparison with the prototype vector ACE-CD harbouring the wildtype yeast CD gene
revealed a three-fold increased CD-specific conversion of 5-FC to 5-FU in infected cells and a
markedly higher genetic stability of the clinical vector candidate Toca 511 [68]. To further
support the production of toxic metabolites in infected cells, the modified CD gene was further
linked as fusion to the gene encoding the yeast uracil phosphoribosyl transferase (UPRT) or,
alternatively, to the human orotate phosphoribosyltransferase (OPRT) gene. It has been
reported that expression of the UPRT gene in the CD-expressing cells leads to increased
sensitivity to 5-FC, as the UPRT converts 5-FU directly to 5-FUMP, from which the active
metabolites 5-FdUMP and 5-FUTP are formed [69,70]. The human OPRT protein, as part of a
multifunctional UMP synthase, is a human analogue of the UPRT, converting 5-FU directly to
5-FUMP with direct impact on the cellular sensitivity towards 5-FU, since downregulation of
this endogenous enzyme was found in tumour cells resistant to 5-FU [71,72]. Moreover,
exogenous expression of the OPRT gene led to increased 5-FU sensitivity in cancer cell lines
in vitro [73]. Despite better individual in vitro cell killing with vectors carrying these fusion
genes, it remains unclear, whether this would be beneficial for therapy, as the highly efficient
5-FC salvage to phosphorylated nucleotides may diminish 5-FU diffusion and thereby the
effects exerted by the bystander mechanism. Furthermore, initial killing of most of the infected
cells might hinder vector spread during the 5-FC-rest period, leading to a reduced antitumor
activity in vivo [68,74]. In addition, serial passaging of these infectious viruses on human
U-87MG glioma cells revealed a decreased genomic stability of vectors containing fusion
constructs as compared to Toca 511, probably due to the size and nature of the inserted
transgene(s) sequences (~500 bp in Toca 511 vs. ~1250 bp in the fusion constructs) [68].
The therapeutic potential of Toca 511 was evaluated in two different intracranial brain tumour
models in immune competent mice (CT26-BALB/c and Tu-2449-B6C3F1) [75]. Treatment of
CT26 brain metastases with three different virus doses (1x10e6, 1x10e5, 1x10e4 transforming
units (TU)/g brain weight) plus 5-FC administration initiated nine days after intratumoral virus
injection at 500 mg/kg given i.p. twice a day for always 7 days, followed by 10 days off until
termination of the study, revealed a statistically significant prolongation in median survival
of mice treated with the mid (1x10e5) and high (1x10e6) vector dose as compared to their PBS-
treated counterparts [75]. In a similar experiment mouse Tu-2449 gliomas were treated using
different virus doses (1x10e6, 1x10e5, 1x10e4 and 1x10e3 TU/g brain weight) and 5-FC doses
(500 mg/kg and 50 mg/kg body weight) [75]. 5-FC treatment or PBS treatment as control was
initiated 9 days after vector injection and was given twice a day for 4 days, followed by a 10
day recovery phase. Cycles were repeated until termination of the study [75]. All vector doses
in combination with 5-FC treatment at 500 mg/kg resulted in prolonged survival, as compared
to PBS controls. Mice treated with vector doses of 1x10e4 and 1x10e5 and high dose 5-FC
revealed a significantly prolonged survival when compared to the PBS controls [75]. However,
even the 1x10e5 vector dose level with a rather low prodrug dose of 50 mg/kg 5-FC resulted
in a survival advantage when compared to control. Histological analyses of Tu-2449 tumours
taken before the first, second, and fourth treatment cycle with 500 mg/kg 5-FC revealed tumour
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growth between the first and the second dosing. Most of the tumour tissue however, was no
longer visible and gliosis was evident by the start of the fourth treatment [75].
Currently, Toca 511 is being investigated in clinical trials in the United States in subjects with
recurrent high-grade glioma either as a direct intratumoral vector injection (Phase I/II Study;
NCT01156584; http://www.clinicaltrials.gov) or vector injection at the time of tumour removal
(Phase I Study; NCT01470794 http://www.clinicaltrials.gov).
3.3.2. Secreted therapeutic molecules
Beside direct killing of tumour cells mediated by suicide gene products, different other
therapeutic approaches, e.g. based on the secretion of therapeutic molecules such as cytokines
or single chain antibodies (scFv) directed against specific tumour antigens could be facilitated
by RCR vectors.
To allow secretion of therapeutic molecules from infected cells, a replicating retroviral vector
was constructed by inserting specific transgene sequences to the first codon of the MLV env
gene via a furin cleavage site sequence [26]. The respective fusion protein will be cleaved by
furin proteases in the Golgi and the scFv will be secreted upon release of the new virus particles
from infected cells (for details see above). The resulting vectors were capable of efficiently
transducing susceptible cells, were genetically stable for more than 12 passages and were able
to efficiently mediate intracellular production and secretion of the GM-CSF cytokine and the
functional laminin-specific or T-cell-specific scFv antibody, respectively [27].
Sun and colleagues demonstrated the potential of the human chemokine interferon-gamma-
inducible protein 10 (IP10) gene, delivered and expressed from a MLV-based RCR vectors, to
inhibit tumour growth in vivo [76]. IP10 is known to be a potent inhibitor of angiogenesis,
tumour growth, and metastasis [77,78]. Using human fibrosarcoma HT1080 cells transduced
with the IP10 RCR vector designed as described above in an s.c. xenograft tumour model in
nude mice, significant tumour growth inhibition and a marked reduction in microvessel
density was observed as compared to non-infected HT1080 control mice (tumour volume 190
mm3 vs. 510 mm3) [76]. In addition, both, growth of s.c. tumour xenografts established from
pre-infected murine Lewis lung carcinoma (LLC) cells as well as the formation of lung
metastases from pre-infected murine melanoma B16F10 cells in immunocompetent C57BL/6
mice was significantly reduced [76].
3.3.3. RNA interference
In cancer gene therapy applications, RNAi-expressing RCR vectors can be used to inhibit
tumour growth, invasion and metastasis. The length of the RNA duplex required for efficient
RNAi is not longer than 21-23 bp. Therefore, the insertion of RNAi expression cassettes into
RCR vectors should be well tolerated in respect to genetic stability and spread kinetics of the
vector. The expression of duplex RNA is usually achieved using an expression cassette
consisting of the RNA Pol III promoter transcribing a sequence designed to form a short hairpin
RNA structure (shRNA). MLV-based RCR vectors were constructed encompassing a tran‐
scription cassette consisting of an H1-RNA Pol III promoter inserted in antisense orientation
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into the 3’ UTR of the vector backbone to drive expression of an shRNA sequence targeted
against the epidermal growth factor receptor (EGFR) gene or the STAT3 gene [30]. To allow
monitoring of infection efficiency, these vectors also contain the eGFP gene fused into the virus
envelope gene. Insertion of both expression cassettes did not interfere significantly with virus
fitness, and the receptor specificity of the Env protein was not impaired by the introduced
eGFP sequences [28]. The modified vectors replicated rapidly and were genetically stable over
several infection cycles. In addition, silencing of EGFR and STAT3 target gene expression in
cells infected to levels of 80 – 95 % was shown to be highly efficient [30].
An improved, second generation MLV-based RNAi transfer vector suitable for in vivo
application was recently described [79]. This RCR vector encodes miRNA modified shRNA
sequences specifically targeting the eGFP and luciferase reporter genes under control of the
small nuclear U6 promoter inserted in antisense orientation into the 3’ UTR of the vector. In
HT1080 cells stably expressing eGFP or luciferase, marker gene expression was suppressed by
more than 80 %, even when only 0.1 % of the cells were initially infected with the RCR vectors
[79]. In vivo systemic tail vein administration of 2.9x10e7 of shLuc expressing vector particles
in animals with pre-established subcutaneous HT1080-Luc tumours led to more than 80 %
reduction in luciferase activity compared to uninfected tumours at day 25 post infection [79].
To investigate the effects of downregulation of tumour-promoting proteins, PLK1- and
MMP14-specific shRNA expression cassettes were inserted into the vector. Upon infection of
target cells, PLK1 and MMP14 mRNA and protein levels were reduced [79]. MLV-shPLK-
infected cells were trapped in the G2-phase of the cell cycle at day 3 post infection, followed
by induction of apoptosis at day 5 post infection. MLV-shMMP14 infected cells showed
reduced MMP2 activity consistent with a reduced invasion capacity by ~75 % as compared to
non-infected cells [79]. Tumour growth of MLV-shMMP14 infected HT1080-Rec-1 cells in
immunodeficient mice was significantly and substantially reduced in comparison to controls.
Similarly, direct intratumoral application of 1x10e6 of shPLK1 expressing vector particles in
animals with pre-established subcutaneous HT1080 xenografts led to a significantly reduced
tumour growth in comparison to the controls [79].
3.4. Safety of MLV-based RCR vectors
Up to now, a variety of different therapeutic approaches have been utilized in context of RCR
vectors. High levels of vector spread, infection efficiency, and therapeutic gene expression
have been detected leading to an efficacious therapeutic option for the treatment of cancer.
From data on the eradication of tumour mass in animal models existing so far, a clear benefit
of the RCR mediated tumour therapy is indicated. However, the use of replicating retroviral
vectors also bears a number of risks which have to be identified and analysed.
In particular, 3 major concerns directly related to the use of RCR vectors have to be taken into
consideration: (i) the risk of insertional mutagenesis due to integration of the vector genome
into the host cell DNA, a step that can trigger the transformation of normal cells into tumour
cells, (ii) the spread of viral vectors throughout the body of the patient causing viraemia, and
(iii) the infection of dividing non-tumour cells and their loss due to therapeutic intervention
leading to severe side effects.
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The risk of insertional oncogenesis is an issue associated with the use of retroviral vectors in
general, irrespective if they are replication-deficient or replication-competent. With RCR
vectors this concern might be more substantial as due to the replicating nature more cells might
be affected and multiple infections of the single cell might occur. On the other hand, in tumour
therapy it is intended to kill the infected cells. Hence, due to this, insertional oncogenesis
should not be an issue unless infected cells are resistant to treatment or got infected with an
RCR vector which is reverted to wild-type due to genetic instability and thus is not able to
exert its therapeutic potential.
The use of replication-competent retroviral vectors might also bear the risk of uncontrolled
spread of vectors throughout the human body, resulting in infection of dividing cells other
than the tumour cells itself. Non-dividing cells should not be infected as MLV-based vectors
are thought to transduce dividing cells only, and, as most cells in the adult human body are
non-dividing, virus spread should be limited. Moreover, some cell types, such as dividing
human primary T-lymphocytes have only a low capacity to produce MLV-based RCR and, in
addition, the produced virions are largely non-infectious [80]. Nevertheless, in case of
unintended virus spread and high risk of viraemia, an early systemic intervention with
antiretroviral drug(s) could be implemented to limit viral load [81]. Recent findings, on the
other hand, suggest that the host range of MLV-based RCR vectors might include also post-
mitotic and other growth-arrested cells in mammals [37]. Therefore, the issue of RCR-vector
dissemination outside of the tumor mass is of particular concern in clinical studies employing
RCR vectors and thus should be addressed in respective biodistribution studies.
For RCR biodistribution studies, sensitivity of the analysis is of utmost importance. Techniques
based on conventional PCR, real-time PCR, flow-cytometry and immunohistochemical
detection were employed so far to analyse the infection range of RCR vectors in animal models.
In an early report, Logg and colleagues analysed the presence of the eGFP transgene in the
DNA extracted from tumour tissue as well as from a variety of extratumoral tissues including
spleen, lung, kidney, liver, and heart obtained from nu/nu BALB/c mice harbouring s.c.
xenografts 7 weeks after intratumoral application of 6x10e3 RCR vector particles [22]. A PCR
assay detecting 140 copies of GFP in a background of 100,000 equivalents of untransduced
genomic DNA (transduction level 0.14 %) was employed [22]. Transgene sequences have been
detected in tumour samples only. These data were further supported by flow cytometric
analysis of the same tissues [22]. By improving this PCR assay, Wang et al. were able to detect
as few as 35 copies of proviral DNA in 0.5 µg of genomic DNA. In an orthotopic glioma model
in nude mice, in which animals were intratumorally inoculated with 1.2x10e4 virus particles,
proviral sequences have been detected in tumour tissue, but not in contralateral brain paren‐
chyma, bone marrow, GI tract, liver, kidney, spleen, lung, and skin [56]. Using a PCR driven
detection method, eGFP transgene sequences could not be observed in normal tissues sur‐
rounding the injected tumours in a s.c. bladder tumour xenograft model in nu/nu BALB/c mice
[62, 64]. No signals have been obtained in distant organs such as brain, liver, spleen, lung,
bladder, kidney, heart, ovary, uterus, and stomach in an orthotopic model of bladder cancer,
when RCR vectors were administered intravesically [62, 64].
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By detection of CD gene-specific sequences by PCR at a detection limit of 400 copies per 100,000
cell genomes (600 ng of gDNA, transduction level 0.4 %), Tai and co-workers were able to
determine proviral sequences in the transduced glioma tissue, but observed no extratumoral
spread to and in any of the tissue examined (lung, liver, oesophagus and stomach, intestine,
spleen, kidney, skin, bone marrow, contralateral normal brain) in an orthotopic glioma model
in nude mice intratumorally injected with 1.2x10e4 virus particles [57]. However, all of these
studies had been based on the detection of the non-viral transgene (e.g. GFP, CD, PNP, etc.).
Hence, putative spread of vectors which have lost the transgene or parts of it will not be
considered in these analyses.
In an immunocompetent intracranial RG2-glioma model performed in Fischer 344 rats,
tumours were injected with 1x10e6 of CD expressing RCR vector particles followed by 5-FC
or PBS treatment initiated 10 days later [58]. Organs from moribund animals were collected
and quantitative real-time PCR targeting the MLV env gene was performed [58]. There was
no evidence of presence of the env gene from the RCR vector in systemic tissues carrying highly
mitotic cells such as lung, liver, kidney, spleen, bone marrow, skin, oesophagus, intestine, and
testis [58]. Using this highly sensitive technique which enables detection of 20-35 copies in
50,000 cellular genomes, Hiraoka et al. analysed RCR vector biodistribution in a mouse hepatic
metastasis model using BALB/c mice and the syngeneic colon carcinoma cell line CT26 [60,61].
After locoregional delivery of 2x10e4 of RCR vector particles either expressing the eGFP or CD
transgene, via intrasplenic injection followed by splenectomy, no detectable virus-related
signals were observed in genomic DNA extracted from peritumoral normal liver tissue, bone
marrow, lung, kidney, small intestine, and colon. As expected, proviral RCR signals were
highly abundant in genomic DNA from RCR-transduced tumour tissues with 3,000 – 16,600
proviral copies per 50,000 cells [60,61]. The copy number was increased in DNA obtained from
ACE-CD/PBS-treated control animals (11,000 – 16,600 copies/50,000 cells) compared to ACE-
CD/5-FC-treated animals (8,000 – 11,000 copies/50,000 cells) [61]. Optical imaging analyses,
flow cytometric analyses as well as immunohistochemistry using an anti-eGFP antibody
consistently revealed strongly positive eGFP signals in the tumour masses but not in the other
organs mentioned above [60].
Biodistribution of  RCR vectors after  intravenous injection into immune deficient as well
as immune competent mice was analysed by Solly and colleagues [25].  Two weeks after
RCR vector injection,  a 4070Aenv-based quantitative real-time PCR revealed presence of
proviral genomes in bone marrow and spleen of nude mice. On the contrary, no proviral
genomes could be detected in any tissue from immunocompetent animals, which empha‐
sizes the potency of anti-MLV specific immune responses [25]. In vivo biodistribution of
wt-MLV and MMP-activatable RCR vectors and their ability to reach tumour tissue after
systemic administration was analysed in CB17-SCID mice using an optimized PCR meth‐
od detecting up to 50 copies of proviral DNA in 300 ng of genomic DNA [48]. After in‐
travenous injection of RCR vectors corresponding to 60 U of RT activity into tumour-free
mice, tissues were analysed at different time points after virus injection. A strong signal
in spleen and weak signals in liver and bone marrow were obtained after administration
of  wt-MLV  vector  one  day  after  infection.  After  two  weeks,  wt-MLV  sequences  were
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found in lung,  spleen,  liver,  heart,  bone marrow,  and muscle,  but  not  in  brain.  The in‐
crease in PCR signal intensity over time suggests continuous virus replication. This was
further supported by the presence of  infectious virus in the blood of  these animals.  On
the contrary,  no positive signals were detected in mice infected with the MMP-activata‐
ble  RCR vectors  [48].  A similar  experiment  was  performed with  U-87MG and HT-1080
s.c.  tumour-bearing mice to quantify the virus load in the tumour tissue. Again, animals
were injected intravenously with similar amounts of wt-MLV and MMP-activatable RCR
vectors and genomic DNA was analysed 2 weeks later. For all viruses, tumour tissue re‐
vealed the highest virus load reaching 100 % of cells in case of the non-targeted wt-MLV
and up to 30 % of cells  for MMP-activatable RCR vectors [48].  In addition,  wt-MLV in‐
fected on average 32 % of the cells in the bone marrow, 11 % of the cells in spleen, and
6 % of the cells  in liver,  whereas the MMP-activatable RCR vector infected only 0.02 %
of cells in these organs [48].  Interestingly,  the load of wt-MLV in bone marrow and the
other  extratumoral  organs  in  tumour-bearing animals  was generally  lower  compared to
those obtained in tumour-free animals [48].
Recently, Ostertag et al. reported biodistribution of the clinical vector Toca 511 after intra‐
tumoral administration in an immunocompetent mouse model of brain cancer using aqua‐
ntitative  real-time  PCR  technique  to  detect  integrated  provirus  sequences  with  high
sensitivity  (10-25  copies  per  µg  of  gDNA)  [75].  Two animal  models  based  on  different
mouse strains had been Involved; BALB/c mice permissive for virus infection, and poorly
permissive  C57BL/6  mice.  In  these  animal  models  10e5  and  10e6  RCR  vector  particles
have been injected intracranially  into the tumor mass.  Quantitative DNA analyses  were
performed on samples from mice which survived for 90 days and 180 days for the CT26-
BALB/c model and the Tu-2449-B6C3F1 model,  respectively.  In the CT26-BALB/c model,
vector  spread to  other  tissues,  particularly  to  lymphoid  organs  (thymus,  spleen,  lymph
node, blood) was detectable [75]. Up to 5x10e5 proviral copies/µg gDNA were detected in
thymus,  up to 1.5x10e5 proviral  copies/µg gDNA in samples from salivary gland,  oeso‐
phagus,  lung,  heart,  spleen,  lymph  node,  and  blood,  and  less  than  5x10e3  proviral
copies/µg gDNA in samples from skin,  ovary,  intestine,  liver,  kidney,  spinal  cord,  bone
marrow, cerebellum and brain [75]. In the Tu-2449-B6C3F1 model vector spread was ob‐
served at low levels only. Less than 5x10e3 proviral copies/µg gDNA were detected and
interestingly the oesophagus was the organ in which the proviral copy number was high‐
est.  The  difference  in  viral  distribution  observed  in  both  model  systems  could  be  ex‐
plained by the presence of different APOBEC3 alleles in these mouse strains. BALB/c mice
have been shown to carry an allele that does not restrict MLV, whereas B6C3F1 mice car‐
ry an active allele [82]. Both mouse strains produced antibodies against Toca 511 [75].
The issue of biodistribution of the vector to non-target sites, as well as the expression of the
therapeutic gene in off-target cells could be addressed best by infection targeting of the vector
or expression targeting of the therapeutic gene to cells of the tumour. This approach has already
been applied using tumour- and tissue-specific regulatory sequences to drive virus replication
and transgene expression, and by modifying the viral envelope protein to allow transduction
in a tissue/tumour specific manner.
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4. Conclusion
Very recently, RCR vectors have been employed as a novel gene transfer vehicle for the
treatment of cancer. Due to their dense genome organisation and the need for presence of all
virus genes to allow vector replication, an only limited capacity for the introduction of foreign
sequences is available, rendering the design of such vectors rather challenging. Nevertheless,
different vector designs in respect to transgene location and mode of transgene expression
have been elaborated. Their analysis in in vitro and in vivo studies revealed that the vectors
are genetically stable over several replication cycles and result in an efficient delivery of the
therapeutic gene into solid tumours in various animal models. On the other hand, different
risks are associated with the use of RCR vectors, such as the risk of insertional tumorigenesis
of non-target cells or the risk of inadvertent vector spread resulting in severe side effects. Such
risks need to be carefully examined in appropriate non-clinical studies. In case they can be
adequately addressed and dispelled, RCR vectors will be a promising option for efficient
tumour therapy in humans.
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